Related Experiment Video
Updated: Feb 10, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Androgen blockade based clinical trials landscape in triple negative breast cancer
Yaqin Shi1, Fang Yang1, Doudou Huang1
1Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Abstract:
Androgen receptor (AR) targeted treatment has shown promising preliminary results in triple negative breast cancer (TNBC). Identification of AR-associated signaling pathways is of great significance for in-depth understanding of their roles in pathogenesis of TNBC. To meet this objective, preclinical and clinical studies were conducted to clarify the biological interactions of AR signaling and combination strategies based on AR-targeted therapy. Biologically, AR signaling in TNBC which not only interacts with a network of key pathways, involving PI3K/AKT/mTOR, cell cycle, and DNA damage repair pathways, but mediates pivotal processes of tumor initiation and immunogenic modulation, may present an opportunity to overcome the insensitivity of single AR-targeted therapy. Research in investigating androgen-blockade based combination therapy in this aggressive tumor has demonstrated promising benefit in preclinical studies, and comparable clinical trials of combined strategies with CDK4/6 inhibitors, PI3K inhibition, chemotherapy, and immunotherapy, are ongoing. Accordingly, clinical interpretation of AR-related biological interactions, aiming at combined blockade of the signaling pathways may pave a new way for endocrine-based therapy in the treatment of TNBC.
Insights
Androgen receptor (AR) targeted therapy shows promise for triple-negative breast cancer (TNBC). Combining AR blockade with other treatments may overcome resistance and improve outcomes for TNBC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- Triple-negative breast cancer (TNBC) remains a challenging subtype with limited targeted therapies.
- Androgen receptor (AR) signaling is increasingly recognized as a potential therapeutic target in TNBC.
- Understanding AR-associated pathways is crucial for developing effective treatment strategies.
Purpose of the Study:
- To elucidate the biological interactions of AR signaling in TNBC.
- To explore combination strategies involving AR-targeted therapy.
- To identify new avenues for endocrine-based treatment in TNBC.
Main Methods:
- Preclinical studies investigating AR signaling pathways.
- Clinical studies evaluating combination therapies.
- Analysis of AR's interaction with PI3K/AKT/mTOR, cell cycle, and DNA damage repair pathways.
Main Results:
- AR signaling interacts with key pathways (PI3K/AKT/mTOR, cell cycle, DNA repair) in TNBC.
- AR signaling influences tumor initiation and immune modulation.
- Preclinical studies show benefits of androgen-blockade combination therapy.
- Clinical trials combining AR-targeted therapy with CDK4/6 inhibitors, PI3K inhibitors, chemotherapy, and immunotherapy are ongoing.
Conclusions:
- AR signaling plays a pivotal role in TNBC pathogenesis.
- Combination therapies targeting AR and associated pathways offer a promising strategy.
- Clinical interpretation of AR-related interactions may lead to novel endocrine-based treatments for TNBC.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Neuromuscular Junction And Blockade
Trial and Error and Algorithm
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....

